PriceTargets.com logo

Guardion Health Sciences - GHSI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.68
  • Forecasted Upside: -86.94%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$5.17 As of 03/24/2023 01:00 AM ET
▲ +0.17 (3.40%)

This chart shows the closing price for GHSI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Guardion Health Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GHSI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GHSI

Analyst Price Target is $0.68
▼ -86.94% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Guardion Health Sciences in the last 3 months. The average price target is $0.68, with a high forecast of $0.75 and a low forecast of $0.60. The average price target represents a -86.94% upside from the last price of $5.17.

This chart shows the closing price for GHSI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Guardion Health Sciences.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/18/2022Ascendiant Capital MarketsInitiated CoverageBuy$0.75Low
5/13/2022Maxim GroupReiterated RatingBuy$0.60High
3/8/2022Maxim GroupInitiated CoverageBuy$0.60Medium
(Data available from 3/26/2018 forward)

News Sentiment Rating

1.55 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Guardion Health Sciences logo
Guardion Health Sciences, Inc.is a clinical nutrition and diagnostics company, which develops medical foods and medical devices in the ocular health space and develops nutraceutical products to provide supportive health benefits to consumers. The company was founded by Michael Favish in 2009 and is headquartered in Houston, TX.
Read More

Today's Range

Now: $5.17
Low: $4.96
High: $5.17

50 Day Range

MA: $6.60
Low: $4.66
High: $8.10

52 Week Range

Now: $5.17
Low: $4.66
High: $13.80

Volume

4,448 shs

Average Volume

9,226 shs

Market Capitalization

$6.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Guardion Health Sciences?

The following Wall Street research analysts have issued stock ratings on Guardion Health Sciences in the last year: Ascendiant Capital Markets, and Maxim Group.
View the latest analyst ratings for GHSI.

What is the current price target for Guardion Health Sciences?

2 Wall Street analysts have set twelve-month price targets for Guardion Health Sciences in the last year. Their average twelve-month price target is $0.68, suggesting a possible downside of 86.9%. Ascendiant Capital Markets has the highest price target set, predicting GHSI will reach $0.75 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $0.60 for Guardion Health Sciences in the next year.
View the latest price targets for GHSI.

What is the current consensus analyst rating for Guardion Health Sciences?

Guardion Health Sciences currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GHSI will outperform the market and that investors should add to their positions of Guardion Health Sciences.
View the latest ratings for GHSI.

What other companies compete with Guardion Health Sciences?

Other companies that are similar to Guardion Health Sciences include Timber Pharmaceuticals, Phio Pharmaceuticals, Kintara Therapeutics, Artelo Biosciences and NeuBase Therapeutics. Learn More about companies similar to Guardion Health Sciences.

How do I contact Guardion Health Sciences' investor relations team?

Guardion Health Sciences' physical mailing address is 15150 AVENUE OF SCIENCE SUITE 200, SAN DIEGO CA, 92128. The company's listed phone number is (800) 873-5141 and its investor relations email address is [email protected] The official website for Guardion Health Sciences is www.guardionhealth.com. Learn More about contacing Guardion Health Sciences investor relations.